Abstract:Objective To investigate the mRNA expression of SMAD9 in lung adenocarcinoma, and its relationship with clinicopathological parameters, survival and prognosis, so as to provide some valuable references for the screening and postoperative survival. Methods The expression of SMAD9 in tumor tissues (510 cases) and adjacent normal tissues (59 cases) of lung adenocarcinoma patients and its relationship with clinicopathological parameters and postoperative survival were analyzed based on the Cancer Genome Atlas (TCGA) database. The expression of SMAD9 in tumor tissues and adjacent normal tissues of lung adenocarcinoma patients, HBE malignant transformed cells induced by 3-MCA and lung adenocarcinoma cells were detected by quantitative real-time RT-PCR (qRT-PCR) and Western blotting. The effect of SMAD9 overexpression and interference on cell proliferation was detected by CCK-8 assay. Results The mRNA expression analysis of SMAD9 in TCGA database showed that the expression of SMAD9 was significantly lower in lung adenocarcinoma than adjacent normal tissues (P < 0.01). The results of qRT-PCR and Western blotting also showed that the expression of SMAD9 was significantly down-regulated in 3-MCA-induced HBE malignant transformed cells and lung adenocarcinoma tissues and cell lines (P < 0.05). The down-regulation of SMAD9 expression was closely correlated with N grade and tumor grade (P < 0.05). ROC curve analysis indicated that the mRNA expression of SMAD9 was a sensitive indicator of lung adenocarcinoma (AUC=0.903, 95%CI=0.868~0.938, P < 0.001). Kaplan-Meier analysis displayed that the survival time of patients with low expression of SMAD9 was significantly shorter than those with high expression (P < 0.05). Overexpression of SMAD9 inhibited the proliferation of lung adenocarcinoma cells (P < 0.01), and the proliferation of HBE cells was significantly enhanced after interfering with SMAD9 expression as compared with the control cells (P < 0.01). Conclusion SMAD9 gene expression is down-regulated in the incidence and development of lung adenocarcinoma. The expression of SMAD9 may be of great value for the screening and postoperative survival of lung adenocarcinoma patients.

POD-02.08: the Positive Expression of ADAM9 Protein Was Relative with Disease Progression to Hormonal Refractory and Poor Prognosis for Advanced Prostate Cancer

ADAM9 Decreases in Castration Resistant Prostate Cancer and is a Prognostic Factor for Overall Survival

The High Expression of PTPRH is Associated with Poor Prognosis of Human Lung Adenocarcinoma

Expression of ADAM9 in Breast Cancer and Its Clinical Significance

ADAM9 Mediates Triple-Negative Breast Cancer Progression Via AKT/NF-κB Pathway.

A pan-cancer study of ADAM9's immunological function and prognostic value particularly in liver cancer

The Clinicopathological Significance and Prognostic Value of Programmed Death-Ligand 1 in Prostate Cancer: a Meta-Analysis of 3133 Patients

Expression and Clinical Significance of ADAM8 Mrna in Breast Cancer

WITHDRAWN: A disintegrin and metalloprotease 8 (ADAM8) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis

Expression of Adam28 As a Prognostic Biomarker of Survival in Patients with Early-Stage Non-Small Cell Lung Cancer.

Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches

Clinical significance of the expression of ADAM9 in colon carcer

Overexpression of a disintegrin and metalloproteinase 9 (ADAM9) in relation to poor prognosis of patients with oral squamous cell carcinoma

Expression and its clinical significance of CD9 protein in pancreatic cancer

Clinical Significance of ADAM10 Expression in Laryngeal Carcinoma.

The Expression and Significance of HDGF and ADAM9 in Esophageal Cancer

Expression and clinical significance of SMAD9 in lung adenocarcinoma

Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis

CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.

Reduced Expression of ADAM8 and Its Role in Breast Cancer

Overexpression of ADAM9 Promotes Colon Cancer Cells Invasion.